Ignite Creation Date:
2024-05-06 @ 4:40 PM
Last Modification Date:
2024-10-26 @ 2:14 PM
Study NCT ID:
NCT05054751
Status:
COMPLETED
Last Update Posted:
2022-06-13
First Post:
2021-08-13
Brief Title:
GB491 Combined With Fulvestrant for HR HER2- Locally Advanced or Metastatic Breast Cancer
Sponsor:
Genor Biopharma Co Ltd
Organization:
Genor Biopharma Co Ltd
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Phase III Clinical Trial of GB491 Combined With Fulvestrant in Subjects With HR HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed on Prior Endocrine Therapy
Status:
COMPLETED
Status Verified Date:
2021-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
GB491-004 is a multicenter randomized double-blind placebo-controlled Phase III study to evaluate the efficacy and safety of GB491 in combination with fulvestrant in patients with HR-positive HER2-negative locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None